A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance

Table 3 Details on Cisplatin

Drug	Source	Approval number	Specification	Diluent	Concentration (μg/ml)
Cisplatin	QiLu Pharmaceutical (Hainan) Co., Ltd	H20073652	10 mg	phosphate-buffered saline (PBS)	1, 2, 4, 8, 16, 32

ISSN: 1757-2215